

# UCSF

## UC San Francisco Previously Published Works

### Title

Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans

### Permalink

<https://escholarship.org/uc/item/4xn3w34t>

### Journal

Gut, 69(1)

### ISSN

0017-5749

### Authors

Che, Li  
Chi, Wenna  
Qiao, Yu  
et al.

### Publication Date

2020

### DOI

10.1136/gutjnl-2018-317581

Peer reviewed



OPEN ACCESS

ORIGINAL ARTICLE

# Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans

Li Che,<sup>1,2</sup> Wenna Chi,<sup>3,4</sup> Yu Qiao,<sup>2,5</sup> Jie Zhang,<sup>1,2</sup> Xinhua Song,<sup>2</sup> Ye Liu,<sup>3</sup> Lei Li,<sup>6</sup> Jiaoyuan Jia,<sup>2,7</sup> Maria G Pilo,<sup>8</sup> Jingxiao Wang,<sup>2,9</sup> Antonio Cigliano,<sup>10</sup> Zhilong Ma,<sup>3</sup> Wenhua Kuang,<sup>3</sup> Zefang Tang,<sup>11,12</sup> Zemin Zhang,<sup>11,12</sup> Guanghou Shui,<sup>13</sup> Silvia Ribback,<sup>10</sup> Frank Dombrowski,<sup>10</sup> Matthias Evert,<sup>14</sup> Rosa Maria Pascale,<sup>8</sup> Carla Cossu,<sup>8</sup> Giovanni Mario Pes,<sup>8</sup> Timothy F Osborne,<sup>15</sup> Diego F Calvisi,<sup>8</sup> Xin Chen ,<sup>2</sup> Ligong Chen<sup>3,4</sup>

► Additional material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2018-317581>).

For numbered affiliations see end of article.

## Correspondence to

Dr Diego F Calvisi, Department of Medical, Surgical, and Experimental Sciences, University of Sassari, via Padre Manzella 4, 07100 Sassari, Italy; [calvisid@uniss.it](mailto:calvisid@uniss.it), Dr Xin Chen, UCSF, 513 Parnassus Avenue, San Francisco, CA 94143, USA; [xin.chen@ucsf.edu](mailto:xin.chen@ucsf.edu) and Dr Ligong Chen, D410 Medical Science Building, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China 100084; [ligongchen@tsinghua.edu.cn](mailto:ligongchen@tsinghua.edu.cn)

Received 12 September 2018  
Revised 14 March 2019  
Accepted 15 March 2019  
Published Online First  
6 April 2019



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Che L, Chi W, Qiao Y, et al. *Gut* 2020;**69**:177–186.

## ABSTRACT

**Objective** Increased de novo fatty acid (FA) synthesis and cholesterol biosynthesis have been independently described in many tumour types, including hepatocellular carcinoma (HCC).

**Design** We investigated the functional contribution of fatty acid synthase (*Fasn*)-mediated de novo FA synthesis in a murine HCC model induced by loss of *Pten* and overexpression of *c-Met* (*sgPten/c-Met*) using liver-specific *Fasn* knockout mice. Expression arrays and lipidomic analysis were performed to characterise the global gene expression and lipid profiles, respectively, of *sgPten/c-Met* HCC from wild-type and *Fasn* knockout mice. Human HCC cell lines were used for in vitro studies.

**Results** Ablation of *Fasn* significantly delayed *sgPten/c-Met*-driven hepatocarcinogenesis in mice. However, eventually, HCC emerged in *Fasn* knockout mice. Comparative genomic and lipidomic analyses revealed the upregulation of genes involved in cholesterol biosynthesis, as well as decreased triglyceride levels and increased cholesterol esters, in HCC from these mice. Mechanistically, loss of *Fasn* promoted nuclear localisation and activation of sterol regulatory element binding protein 2 (*Srebp2*), which triggered cholesterol synthesis. Blocking cholesterol synthesis via the dominant negative form of *Srebp2* (*dnSrebp2*) completely prevented *sgPten/c-Met*-driven hepatocarcinogenesis in *Fasn* knockout mice. Similarly, silencing of *FASN* resulted in increased *SREBP2* activation and hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase (*HMGCR*) expression in human HCC cell lines. Concomitant inhibition of *FASN*-mediated FA synthesis and *HMGCR*-driven cholesterol production was highly detrimental for HCC cell growth in culture.

**Conclusion** Our study uncovers a novel functional crosstalk between aberrant lipogenesis and cholesterol biosynthesis pathways in hepatocarcinogenesis, whose concomitant inhibition might represent a therapeutic option for HCC.

## INTRODUCTION

The global incidence of primary liver cancer has progressively increased over the last decades.

## Significance of this study

### What is already known on this subject?

- Aberrant activation of fatty acid synthase (*FASN*) and related de novo lipogenesis is major metabolic event along hepatocellular carcinoma (HCC) development.
- Targeting *FASN*-mediated de novo lipogenesis is able to inhibit HCC growth in vitro and in vivo.
- Emerging evidence suggests the existence of additional mechanisms supporting HCC cell proliferation and survival in the absence of de novo lipogenesis.

### What are the new findings?

- Loss of *Fasn* and its mediated de novo lipogenesis delays but does not completely prevent oncogene-driven hepatocarcinogenesis in some mouse models.
- Tumour development eventually occurs and is orchestrated by the upregulation of *Srebp2*-driven cholesterol biosynthesis in *Fasn* null mouse liver tumour samples.
- Similar phenotypes are found in human HCC cell lines when they are genetically depleted of *FASN*. These results unveil a novel biochemical crosstalk between de novo lipogenesis and cholesterol biosynthesis pathways along hepatocarcinogenesis.
- Blocking cholesterol biosynthesis completely prevents tumour formation in liver-specific *Fasn* KO mice.
- Concomitant targeting de novo lipogenesis and cholesterol biosynthesis are highly detrimental for the growth of human HCC cells.

Among primary liver malignancies, hepatocellular carcinoma (HCC) is the predominant type.<sup>1</sup> HCC has limited treatment options. The standard care of drugs for the treatment of advanced HCC are the multikinase inhibitors sorafenib and regorafenib, but they display limited efficacy.<sup>2</sup> Thus, there is

## Significance of this study

**How might it impact on clinical practice in the foreseeable future?**

- ▶ Our findings strongly suggest that simultaneous targeting of de novo lipogenesis and cholesterol biosynthesis may be a highly effective strategy for the treatment and prevention of HCC.
- ▶ Furthermore, the same molecular mechanisms might occur (and, thus, could be effectively targeted) in other tumour types as well.

an obvious unmet medical need for new drug targets for HCC treatment.

Metabolic reprogramming is now recognised as one of the cancer hallmarks, and a key event during tumour initiation and progression.<sup>3–4</sup> Among these alterations, de novo lipogenesis consists of the synthesis of endogenous fatty acids (FAs) from acetyl-CoA. Increased de novo lipogenesis has been observed in multiple cancer types.<sup>5</sup> In human HCC, data from our and other laboratories have documented the increased expression of major enzymes associated with de novo lipogenesis, including fatty acid synthase (FASN), in tumour lesions when compared with liver non-neoplastic counterparts.<sup>6,7</sup> Ablation of *Fasn* completely inhibited hepatocarcinogenesis in mice overexpressing an activated form of AKT, either alone or in combination with c-Met.<sup>8,9</sup> However, emerging evidence suggests the existence of additional mechanisms supporting HCC cell proliferation and survival in the absence of de novo lipogenesis. Indeed, silencing of *FASN* delays, but does not completely inhibit, in vitro growth of HCC cell lines.<sup>7,10</sup> Importantly, in a liver-specific *Pten* and *Tsc1* double KO mouse HCC model, silencing of *Fasn* via AAV-sh*Fasn* significantly decreased, but did not completely prevent, HCC formation.<sup>11</sup>

Dysregulated cholesterol biosynthesis is another metabolic event frequently observed in HCCs. HMG-CoA reductase (HMGCR) is the rate limiting enzyme in cholesterol biosynthesis and the target of cholesterol-lowering drugs statins. Previous findings indicate the upregulation of HMGCR expression in human HCC samples.<sup>7,12</sup> Noticeably, the use of statins has been associated with reduced risk of HCC development in large epidemiological studies, suggesting a potential tumour supporting role of the cholesterol biosynthesis pathway in this disease.<sup>13,14</sup> Statins have also been shown to inhibit human HCC cell proliferation in culture as well as c-Myc-driven HCC development in mice.<sup>15–17</sup>

In this manuscript, we investigated the requirement of *Fasn* in sgPten/c-Met mouse HCC.<sup>18</sup> Our results unveil novel biochemical crosstalk between de novo lipogenesis and cholesterol biosynthesis pathways along hepatocarcinogenesis.

**MATERIALS AND METHODS****Hydrodynamic injection and mouse monitoring**

*Fasn*<sup>fl/fl</sup> mice in C57BL/6 background were described previously.<sup>19</sup> *AlbCre* mice in C57BL/6 background<sup>20</sup> were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA). *Fasn*<sup>fl/fl</sup> mice were crossed with *AlbCre* mice to eventually generate liver-specific *Fasn* knockout mice (*Fasn*<sup>LKO</sup> mice). The physiological phenotype of *Fasn*<sup>LKO</sup> mice has been extensively characterised.<sup>21</sup> Both male and female mice were used in the study, and no sex-dependent differences were detected. Hydrodynamic transfection was performed as described.<sup>22</sup> Mice were monitored weekly,

ethanased and liver tissues collected when they developed large abdominal masses or by 40–50 weeks postinjection. The detailed mouse experiment data are available in online supplementary table S1. All mice were housed, fed and monitored in accordance with protocols approved by the Committee for Animal Research at the University of California, San Francisco.

**Human tissue samples**

Sixty-five frozen HCC and corresponding non-tumourous surrounding livers (SL) were used. Clinicopathological features of patients with liver cancer are summarised in online supplementary table S2. HCC specimens were collected at the Medical University of Greifswald (Greifswald, Germany). Informed consent was obtained from all individuals.

**Statistical analysis**


Data were analysed using the Prism 6 software (GraphPad, San Diego, California, USA). Comparisons between two groups were performed with two-tailed unpaired t-test. Statistical differences among the various groups were assessed with the Tukey-Kramer's test. Kaplan-Meier method and log-rank test were used for survival analysis. All graphs are the mean ± SEM. P values <0.05 were considered to be statistically significant.

Additional information can be found in online supplementary materials and methods.

**RESULTS****Ablation of *Fasn* delays sgPten/c-Met-induced hepatocarcinogenesis in mice**

We discovered that lipogenic proteins are strongly induced in hepatocellular lesions in sgPten/c-Met mice.<sup>18</sup> To investigate the requirement of *Fasn* and mediated de novo lipogenesis in sgPten/c-Met-driven hepatocarcinogenesis, conditional *Fasn* KO mice (*Fasn*<sup>fl/fl</sup> mice) were employed.<sup>19</sup> Specifically, two distinct approaches were applied. In the first approach, we bred *AlbCre* mice with *Fasn*<sup>fl/fl</sup> mice to eventually generate *Fasn*<sup>LKO</sup> mice. sgPten and c-Met plasmids were injected into *Fasn*<sup>LKO</sup> mice (n=10) as well as control *Fasn*<sup>fl/fl</sup> mice (n=4) (figure 1A). All sgPten/c-Met-injected *Fasn*<sup>fl/fl</sup> mice developed high burden of liver tumours by 8–10 weeks postinjection and were required to be euthanised, in agreement with previous data (online supplementary table S1).<sup>18</sup> In contrast, at this time point, all sgPten/c-Met-injected *Fasn*<sup>LKO</sup> mice appeared to be healthy with no palpable abdominal masses. However, hepatocarcinogenesis was delayed but not abolished by *Fasn* deletion in sgPten/c-Met-injected *Fasn*<sup>LKO</sup> mice, which exhibited a high burden of malignant lesions within 14–40 weeks postinjection (figure 1B and online supplementary table S1). Histologically, sgPten/c-Met co-expression led to the formation of pure HCCs in the liver of *Fasn*<sup>fl/fl</sup> and *Fasn*<sup>LKO</sup> mice (figure 1C). Immunohistochemical analysis (IHC) showed that all HCCs from wild-type mice expressed high levels of *Fasn* protein, which will be referred to as 'Fasn(+)' HCC, whereas all HCC cells in *Fasn*<sup>LKO</sup> mice showed no *Fasn* expression, which will be referred to as 'Fasn(-)' HCC (figure 1A and C). The levels of ectopically expressed human c-Met as well as the loss expression of *Pten* protein were equivalent in Fasn(+) HCCs and Fasn(-) HCCs (figure 1C,D).

In the second approach, we hydrodynamically injected sgPten, c-Met and Cre plasmids into *Fasn*<sup>fl/fl</sup> mice (sgPten/c-Met/Cre; n=6), thus allowing the deletion of *Pten* together with overexpression of c-Met oncogenes and deletion of *Fasn* in the same subset of mouse hepatocytes. As a control, sgPten, c-Met and pT3EF1α (empty vector) were co-injected into *Fasn*<sup>fl/fl</sup> mice



**Figure 1** Genetic ablation of *Fasn* in the mouse liver delays sgPten/c-Met-driven hepatocellular carcinoma (HCC) formation. (A) Scheme of the experiment. (B) Survival analysis of sgPten/c-Met-induced HCC in *Fasn*<sup>fl/fl</sup> mice (n=4) and in *Fasn*<sup>LKO</sup> mice (n=6). (C) Gross images, H&E and immunohistochemistry of FASN and Pten expression in sgPten/c-Met HCC from *Fasn*<sup>fl/fl</sup> mice (upper panels) and *Fasn*<sup>LKO</sup> mice (lower panels); w.p.i., weeks postinjection; scale bar: H&E, Fasn and Pten; 200  $\mu$ m; Ki67, 100  $\mu$ m. (D) Western blot analysis of c-Met, Pten and Fasn expression in liver tissues.  $\beta$ -Actin and Gapdh were used as loading controls. NL, normal liver tissues.

(sgPten/c-Met/pT3, n=5) (online supplementary figure S1A). All sgPten/c-Met/pT3 mice developed liver tumours by 9–12 weeks postinjection (online supplementary figure S1B), whereas macroscopic and/or histopathological alterations were detected in the livers of sgPten/c-Met/Cre mice between 20 and 51 weeks postinjection (online supplementary figure S1B and online supplementary table S1). Histological and biochemical analyses revealed that HCC lesions from both cohorts expressed the transfected c-Met and displayed loss of Pten. Fasn expression was confirmed to be lost in sgPten/c-Met/Cre HCCs (online supplementary figure S1C).

Mutations of *PIK3CA* occur in ~4% of human HCCs.<sup>23</sup> We previously showed that *PIK3CA*<sup>H1047R</sup> cooperates with c-Met or NRasV12 to promote HCC development in mice (*PIK3CA*/c-Met or *PIK3CA*/Ras).<sup>24</sup> To determine whether the delayed hepatocarcinogenesis induced by loss of *Fasn* could be observed in other murine HCC models, we deleted *Fasn* in *PIK3CA*/c-Met and *PIK3CA*/Ras mice. We found that in all cases, ablation of *Fasn* resulted in significant delay but not suppression of tumour development (online supplementary figure S2–S5).


Altogether, our data indicate that Fasn and its mediated de novo lipogenesis are key metabolic events during hepatocarcinogenesis. However, oncogene-expressing hepatocytes could eventually overcome the loss of *Fasn* and progress into HCC.

### Expression analysis of Fasn regulated genes and pathways in sgPten/c-Met-driven hepatocarcinogenesis

As loss of *PTEN* is more commonly seen than *PIK3CA* mutations in human HCC,<sup>23</sup> we used the sgPten/c-Met HCC model for the subsequent functional studies. Normal liver tissues from *Fasn*<sup>fl/fl</sup> mice (Fasn(+) NL) and *Fasn*<sup>LKO</sup> mice (Fasn(-) NL) were used as controls when necessary. Using Ki67 IHC, we found that tumour cells proliferated at a higher rate in Fasn(+) HCC than Fasn(-) HCC (online supplementary figure S6). Next, we analysed the major signalling pathways downstream of Pten and c-Met. Using Western blot analysis, we found that p-ERK levels did not differ in Fasn(+) and Fasn(-) HCC tissues, indicating that Fasn

does not affect Ras/MAPK cascade during hepatocarcinogenesis (online supplementary figure S7). Of note, p-AKT at S473 was mildly decreased in Fasn(-) HCCs, whereas p-AKT at T308 was significantly downregulated. The decreased p-AKT activity may be due to the decreased expression of rapamycin-insensitive companion of mammalian target of rapamycin (Rictor) (online supplementary figure S7), a key component of mTORC2, consistent with our previous study showing that FASN regulates Rictor stability.<sup>9</sup> Decreased AKT activity led to reduced expression of some AKT downstream effectors, including phosphorylated glycogen synthase kinase-3beta (p-GSK3 $\beta$ ) and phosphorylated proto-oncogene serine/threonine-protein kinase (p-c-Raf), but not phosphorylated forkhead box protein O1 (p-Foxo1) and phosphorylated proline-rich AKT1 substrate 1 (p-PRAS40), in Fasn(-) HCCs (online supplementary figure S7). In addition, mTOR pathway activity, as illustrated by the levels of p-RPS6 and p-4EBP1, was similar in Fasn(+) and Fasn(-) HCCs (online supplementary figure S7).

To further understand how Fasn regulates hepatocarcinogenesis, we performed global gene expression analysis. Four samples from each group (Fasn(+) NL; Fasn(-) NL; Fasn(+) HCC and Fasn(-) HCC) were subjected to microarray experiments. Hierarchical cluster analysis showed distinct gene expression patterns in NL and HCC with or without Fasn, indicating that cancer-related gene signature was dominating in expression analysis (figure 2A and online supplementary dataset S1A). To identify genes that might contribute to Fasn-mediated tumorigenesis, we specifically searched for genes differentially expressed in Fasn(+) versus Fasn(-) HCC samples. We identified 284 differentially expressed genes ( $\log_2$ FoldChange > 1 or  $\log_2$ FoldChange < -1,  $p_{\text{adj}} < 0.05$ ), including 98 upregulated genes and 186 downregulated genes in Fasn(-) HCCs (online supplementary dataset S1B). Interestingly, 32 of the differentially expressed genes were related to lipid catabolism (figure 2B and online supplementary dataset S1C). Pathway analysis of the differentially expressed genes revealed that Srebp signalling pathway was in the top category of the upregulated pathways between Fasn(-) HCC versus



**Figure 2** Microarray data analysis of fatty acid synthase (*Fasn*)(+) and *Fasn*(-) normal liver and hepatocellular carcinoma (HCC). (A) Heat map of four groups of samples ( $n=4$ /each) from *Fasn*(+) NL and HCC as well as *Fasn*(-) NL and HCC ( $|\log_2 FC| > 1$ ,  $p_{adj} < 0.05$ ). (B) Heat map of lipid catabolism-related genes in *Fasn*(-) HCC and *Fasn*(+) HCC. (C) Pathway analysis of the genes that show differences ( $P < 0.05$ ) between *Fasn*(-) and *Fasn*(+) HCC. (D) Summary of the signalling pathways regulating cholesterol and fatty acid synthesis in *Fasn*(-) HCC vs *Fasn*(+) HCC; red arrows indicate deregulated genes, while green arrows indicate deregulated metabolites. NL, normal liver tissues.

*Fasn*(+) HCC. Genes downstream of *Srebp* transcription factors, including those involved in triglyceride biosynthesis, FA biosynthesis and mevalonate pathway, were all found to be upregulated in *Fasn*(-) HCCs (figure 2C). Indeed, expression levels of *Acly* and *Acaca*, which are related to FA biosynthesis, *Elovl6*, an enzyme for very long FA elongation, *Hmgcr*, squalene monooxygenase (*Sqle*) ( $p_{adj} = 0.057$ ), diphosphomevalonate decarboxylase (*Mvd*), which are involved in the mevalonate and cholesterol biosynthesis pathways, were highest in *Fasn*(-) HCCs and cytochrome P450 family 7 subfamily a member 1 (*Cyp7a1*) ( $p_{adj} = 0.205$ ) and cytochrome P450 family 7 subfamily b member 1 (*Cyp7b1*), two key enzymes responsible for cholesterol ester (CE) degradation, were lowest in the same tumours (figure 2B and D). In contrast, several enzymes involved in FA oxidation, including acetyl-CoA acyltransferase 1a (*Acaa1a*), acetyl-CoA acyltransferase 1b (*Acaa1b*) and hydroxysteroid 17-beta dehydrogenase 4 (*Hsd17b4*) ( $p_{adj} = 0.060$ ) were downregulated (online supplementary dataset S1C; figure 2B,C). Carnitine palmitoyltransferase 1a (*Cpt1a*) is the master regulator of FA oxidation, and its levels were similar in *Fasn*(-) HCC and *Fasn*(+) HCC. Thus, we analysed *Cpt1a* protein expression (online supplementary figure S7), and found that *Cpt1a* was expressed at lower levels in *Fasn*(-) HCC, supporting the decreased FA oxidation in *Fasn*(-) tumour cells.

To further validate our observation, we performed qRT-PCR analysis in *Fasn*(+) versus *Fasn*(-) HCCs. Expression levels of acetyl-CoA carboxylase alpha (*Acaca*), ATP citrate lyase (*Acly*), *Hmgcr*, *Sqle*, *Mvd* and *Elovl6* were homogeneously upregulated, whereas *Fasn* expression was strongly downregulated, in *Fasn*(-) HCCs (online supplementary figure S8).

Since FA synthesis and cholesterol production are controlled by *SREBP1* and *SREBP2* transcription factors, respectively,<sup>25</sup> their expression was evaluated. Based on microarray data, *Srebf1*/*Srebf2* mRNA levels did not change significantly in the various cohorts of liver samples. Consistently, total *Srebp1* and *Srebp2* protein levels did not change (figure 3A). However, using nuclear extracts, we found that nuclear levels of *Srebp1* had a


trend to increase and *Srebp2* levels were significantly higher in *Fasn*(-) HCC (figure 3B,C). Using immunohistochemistry, we confirmed the increased nuclear *Srebp1* and *Srebp2* indexes in *Fasn*(-) HCCs (figure 3D,E).

Altogether, expression analysis demonstrates that loss of *Fasn* leads to feedback activation of *Srebp2*, resulting in the increased expression of genes involved in cholesterol biosynthesis.

### Upregulation of cholesterol esters in *Fasn*(-) HCC tissues

We investigated how the loss of *Fasn* modulates lipid metabolisms along hepatocarcinogenesis. We performed lipidomic analysis of *Fasn*(+) NL, *Fasn*(-) NL, *Fasn*(+) HCC and *Fasn*(-) HCC ( $n=6$ /each cohort). Lipid classes were analysed, including neutral lipids, phospholipids, and sphingolipids (online supplementary dataset S2). As shown on the heat map, the alterations of lipids were more profound between *Fasn*(-) versus *Fasn*(+) HCC, and less remarkable between *Fasn*(-) and *Fasn*(+) NL (figure 4A,B). Among the major lipids, CE levels were higher in *Fasn*(+) HCC than in normal liver tissues and highest in *Fasn*(-) HCC. In contrast, triacylglycerols (TAG), diacylglycerols (DAG) and free fatty acids (FFA) were all highest in *Fasn*(+) HCC, whereas loss of *Fasn* led to their decrease (figure 4A,B). When analysing lipid composition based on the mole percentage of total lipids, TAG, which represents ~70% of total lipids in *Fasn*(+) HCCs, dropped to ~40% in *Fasn*(-) HCC. In striking contrast, CE were only ~5% of total lipids in *Fasn*(+) HCCs, but raised to ~20% in *Fasn*(-) HCC (figure 4C). Overall, when specifically comparing lipid profiles between *Fasn*(+) HCC and *Fasn*(-) HCC, TAG, DAG and FFA levels were low, whereas CE levels highest in *Fasn*(-) HCC (figure 4D). Consistently, Oil Red O staining, which mainly stains TAG droplets, revealed extensive positivity in *Fasn*(+) HCC, and loss of staining in *Fasn*(-) HCC (online supplementary figure S9A).

Next, we analysed the FA composition of the various lipid species. Consistent with the loss of *Fasn* in *Fasn*(-) HCC, the concentration of C14:0 (myristic acid) and C16:0 (palmitic



**Figure 3** Expression analysis of fatty acid synthase (*Fasn*) regulated genes and pathways in *Fasn*(+) and *Fasn*(-) mouse hepatocellular carcinoma (HCC) samples. (A) Western blot analysis of total sterol regulatory element binding protein (*Srebp1*) and *Srebp2* protein levels in the liver tissues;  $\beta$ -actin and *Gapdh* were used as loading controls. (B) Western blot analysis of nuclear (n-) *Srebp1* and *Srebp2* in liver tissues; histone H3 and  $\beta$ -tubulin were used as loading controls for nuclear and cytoplasmic fractions, respectively. (C) Quantification of western blot analysis data of nuclear (n-) *Srebp1* and *Srebp2* in *Fasn*(+) and *Fasn*(-) HCC. (D) Immunohistochemical staining of *Srebp1* and *Srebp2* expression of NL, *Fasn*(+) HCC and *Fasn*(-) HCC. Red arrows indicate nuclear staining of *Srebp1* and *Srebp2*. (E) Quantification of the percentage of nuclear (n-) *Srebp1* and *Srebp2* levels using immunostaining in *Fasn*(+) and *Fasn*(-) HCC tissues. Scale bar: 100  $\mu$ m. NL, normal liver tissues.

acid), which are end-products of *Fasn*, were lower in *Fasn*(-) HCC than *Fasn*(+) HCC (figure 4E). In the case of CE, except for C14:0 and C16:0, the levels of most long-term FAs, such as C18:1 and C18:2, were highest in *Fasn*(-) HCC (figure 4E–G). The detailed analyses of FA composition in other lipid species, including TAG, DAG, FFA, phosphatidylcholine, phosphatidylethanolamine and sphingomyelin, are shown in online supplementary figure S10–S15.

When analysing the source of FAs in HCCs, we identified an overall significantly higher contribution of dietary FA in *Fasn*(-) HCC (figure 4H). The results are consistent with the hypothesis that when de novo lipogenesis is inhibited, FA uptake is a major compensatory mechanism for obtaining FA required for tumour growth.

### Deregulation of cholesterol biosynthesis pathway is a major event in *Fasn*(-) HCC


We combined the data from genomics and lipidomics studies. At the gene expression level, loss of *Fasn* in sgPten/c-Met HCC cells resulted in a compensatory increased expression of genes associated with FA and cholesterol biosynthesis downstream of *Srebp1/Srebp2* (figure 2D). However, due to the limitation of FAs, TAG levels decreased in *Fasn*(-) HCC (figure 2D). On the other hand, increased *Srebp2* led to the augmented expression of cholesterol biosynthesis genes, including *Hmgcr*, *Sqle* and *Mvd* (figure 2D), resulting in highest CE levels in *Fasn*(-) HCC (figures 2D and 4D).

In summary, using a systems biology approach by combining genomics and lipidomics analyses, we discovered that loss of de novo lipogenesis may trigger the activation of *Srebp2* and increased cholesterol biosynthesis along hepatocarcinogenesis.

### Co-expression of a dominant negative *Srebp2* (dn*Srebp2*) completely blocks sgPten/c-Met-induced HCC formation in *Fasn*<sup>LKO</sup> mice

Based on these observations, we hypothesised that increased *Srebp2* might compensate for the loss of *Fasn* and related mediated de novo lipogenesis in promoting HCC development in mice. Thus, it would be expected that blocking *Srebp2* prevents sgPten/c-Met-induced hepatocarcinogenesis in *Fasn*<sup>LKO</sup> mice. To test this hypothesis, we co-expressed sgPten/c-Met oncogenes with dn*Srebp2*<sup>25</sup> into *Fasn*<sup>LKO</sup> mice (sgPten/c-Met/dn*Srebp2*; figure 5A). Additional *Fasn*<sup>LKO</sup> mice were hydrodynamically injected with sgPten/c-Met and pT3 empty vector as control (sgPten/c-Met/pT3, figure 5A). All sgPten/c-Met/pT3-injected *Fasn*<sup>LKO</sup> mice were harvested between 15 and 31 weeks postinjection and all but one mouse exhibited high liver tumour burden (figure 5B and online supplementary table S1). In contrast, sgPten/c-Met/dn*Srebp2* mice were aged until 50 weeks postinjection and appeared healthy, with no liver tumour nodules visible (figure 5B and online supplementary table S1). Histological evaluation showed HCC lesions in sgPten/c-Met/pT3 liver tissues, and normal liver in sgPten/c-Met/dn*Srebp2* mice (figure 5C). Furthermore, we analysed apoptosis, inflammation and fibrosis in liver tissues from the different cohorts of injected *Fasn*<sup>LKO</sup> mice. Immunostaining of  $\alpha$ -smooth muscle actin and Sirius Red staining revealed more stromal cells in HCC lesions than those in liver tissues from uninjected *Fasn*<sup>LKO</sup> mice or sgPten/c-Met/dn*Srebp2* *Fasn*<sup>LKO</sup> mice (online supplementary figure S16). Other cellular processes, such as inflammation and apoptosis, were not significantly altered in HCC lesions or sgPten/c-Met/dn*Srebp2* liver tissues (online supplementary figures S17 and S18).

Altogether, the results indicate that co-expression of dn*Srebp2* effectively blocks sgPten/c-Met-induced HCC formation in *Fasn*<sup>LKO</sup> mice. Concomitant inhibition of *Srebp2*-driven




**Figure 4** Lipidomic and fatty acid composition of cholesterol ester (CE) data from normal liver and hepatocellular carcinoma (HCC) tissues with or without fatty acid synthase (Fasn). (A) Heat map of average levels of lipid species concentrations ( $\mu\text{M}$ ) in liver tissues. (B) Amount of lipid species in liver tissues illustrated as concentration ( $\mu\text{M}$ ) of each lipid species. Lipid species with very low concentration are shown in the right corner of the panel. (C) Amount of lipid species in liver tissues illustrated as percentage of each lipid species in the total lipid pool; lipid species with very low percentage of concentration are shown in the right corner of the panel; Fasn(-) HCC vs Fasn(+) HCC, \* $P < 0.05$  and \*\* $P < 0.01$ . (D) Summary of various lipid species differences between Fasn(-) and Fasn(+) HCC. (E) Heat map of species of CE containing different lengths of fatty acids based on the concentrations ( $\mu\text{M}$ ) in liver tissues. (F) Concentration ( $\mu\text{M}$ ) of CE containing different lengths of fatty acids in the liver tissues; CE species with very low concentration are shown in the right corner of the panel. (G) The percentage of CE with different lengths of fatty acids relative to total amount of CE in the liver tissues; Fasn(-) HCC vs Fasn(+) HCC, \* $P < 0.05$  and \*\* $P < 0.01$ . (H) Classification of sources of fatty acids from diet or de novo lipogenesis based on the length of side chains and lipidomic data. NL, normal liver tissues.

cholesterol biosynthesis and Fasn-mediated de novo lipogenesis might completely prevent HCC formation in vivo.

**Functional interplay between de novo lipogenesis and cholesterol biosynthesis pathways in human HCC cell lines**

We investigated whether the same molecular crosstalk occurs in human HCC using a panel of HCC cell lines (online supplementary figure S19). *FASN* gene was silenced in human HCC cells using specific small interfering RNA (siRNA). Knock-down of *FASN* resulted in increased nuclear *SREBP2* protein expression (figure 6A) and activity (online supplementary

figure S20). Furthermore, *FASN* depletion led to the increased expression of *HMGCR* in a *SREBP2*-dependent manner, as silencing of *SREBP2* blocked siFASN-induced *HMGCR* upregulation (figures 6B and online supplementary figure S21). To further validate this observation, *FASN* was deleted via CRISPR/Cas9-based gene-editing technology in the SNU449 HCC cell line (online supplementary figure S22). Two single cell clones, sgFASN.18 and sgFASN.32, were selected; western blot analysis and genomic sequencing confirmed *FASN* deletion (figures 6C and online supplementary figure S22). In both clones, deletion of *FASN* resulted in nuclear localisation of




**Figure 5** dnSrebp2 inhibits sgPten/c-Met-induced hepatocellular carcinoma (HCC) formation in fatty acid synthase (*Fasn*)<sup>LKO</sup> mice. (A) Study design; (B) tumour development incidence curves in sgPten/c-Met/pT3 (n=6) and sgPten/c-Met/dnSrebp2-injected *Fasn*<sup>LKO</sup> mice (n=10); (C) gross images, H&E, Fasn and Ki67 immunohistochemical analysis of sgPten/c-Met/pT3-injected (upper panel) and sgPten/c-Met/dnSrebp2-injected (lower panel) *Fasn*<sup>LKO</sup> mice. w.p.i., weeks postinjection; scale bars: H&E and Fasn; 200  $\mu$ m; Ki67, 100  $\mu$ m.

SREBP2 (figure 6C,D), as well as increased *HMGCR* mRNA expression (figure 6E). Furthermore, consistent with previous studies, sgFASN.18 and sgFASN.32 showed decreased cell proliferation (online supplementary figure S23).


Based on these data, we hypothesised that concomitant inhibition of FASN-mediated de novo lipogenesis and SREBP2/HMGCR-mediated cholesterol biosynthesis might show stronger antitumour growth activity in human HCC cells. We assessed the cell growth rates in a panel of human HCC cells treated with siFASN and siHMGCR or siSREBP2,

either alone or in combination (figures 7A and online supplementary figure S24). While silencing of either *FASN*, *HMGCR* or *SREBP2* alone led to decreased growth in all cell lines, co-transfecting HCC cells with siFASN and siHMGCR or siSREBP2 resulted in significantly stronger growth restraint (figures 7A and online supplementary figure S24). At the molecular level, suppression of *FASN* led to the upregulation of *HMGCR* and *SREBP2* mRNAs as well as of *SREBP2* transcriptional activity and its targets genes (mevalonate kinase [*MVK*], *SQLE* and squalene synthase). Knockdown of



**Figure 6** Silencing of fatty acid synthase (*FASN*) induces activation of sterol regulatory element binding protein 2 (*SREBP2*) and HMG-CoA reductase (*HMGCR*) expression in human hepatocellular carcinoma (HCC) cells. (A) Silencing of *FASN* with siFASN led to increased nuclear *SREBP2* expression in human HCC cell lines; (B) qRT-PCR analysis of mRNA expression of *FASN*, *SREBP2* and *HMGCR* in SNU475 cells treated with various small interfering RNA (siRNA). Similar results were obtained using Hep40, Hep3B, SNU475 and MHCC97H HCC cell lines (online supplementary figure S20).  $P < 0.05$  scrambled control (siSc); scramble siRNA; (a) vs control; (b) vs siSc; (c) vs siFASN; (d) vs siHMGCR; (e) vs siSREBP2; (f) vs siFASN+siHMGCR; (g) vs siFASN+siSREBP2. (C) Western blot analysis of *FASN*, full length (f-) and nuclear (n-) *SREBP2* expression in control, sgFASN.18 and sgFASN.32 subclones of SNU449 cells. (D) Immunofluorescence of *SREBP2* in control, sgFASN.18 and sgFASN.32 subclones of SNU449 cells; scale bar: 10  $\mu$ m. (E) qPCR analysis of *FASN* and *HMGCR* mRNA expression in control, sgFASN.18 and sgFASN.32 subclones of SNU449 cells.





**Figure 7** Concomitant targeting of fatty acid synthase (FASN)-mediated de novo lipogenesis and HMGCR-mediated cholesterol biosynthesis results in increased growth inhibition in human hepatocellular carcinoma (HCC) cell lines. (A) Cell proliferation (upper panel) and apoptosis (lower panel) in Hep40 and SNU475 HCC cells treated with various small interfering RNA (siRNA). Similar results were obtained using Hep3B and MHCC97H HCC cells (online supplementary figure S24).  $P < 0.05$  (a) vs control; (b) vs siSc; (c) vs siFASN; (d) vs siHMGCR; (e) vs siSREBP2; (f) vs siFASN+siHMGCR; (g) vs siFASN+siSREBP2. siSc, scrambled control. (B) Cell proliferation (upper panel) and apoptosis (lower panel) in Hep40 and SNU475 HCC cells treated with C75, atorvastatin or C75+atorvastatin. Similar results were obtained using Hep3B, PLC and MHCC97H HCC cells (online supplementary figure S25).  $P < 0.05$  (a) vs dimethyl sulfoxide (DMSO); (b) vs C75 and (c) vs atorvastatin.

either *HMGCR* or *SREBP2* instead resulted in downregulation of *SREBP2* gene targets while triggering *FASN* upregulation. To further substantiate this observation, we applied a pharmacological approach, by treating HCC cells with the FASN inhibitor C75 and the HMGCR inhibitor atorvastatin, alone or in combination (figures 7B and online supplementary figure S25). Consistently, we found that concomitant treatment of cells with C75 and atorvastatin led to increased growth decline (figures 7B and online supplementary figure S25). As these HCC cell lines have different levels of AKT/mTORC2 activity (online supplementary figure S19), the results suggest that combined inhibition of de novo lipogenesis and cholesterologenesis augments growth inhibition in HCC cells regardless of mTORC2 status.

Collectively, our findings demonstrate that loss FASN triggers the compensatory activation of SREBP2/HMGCR metabolic cascade in human and mouse HCC cells (figure 8). Concomitant targeting of FASN and HMGCR may be required for the effective prevention or treatment HCC (figure 8).

### Negative prognostic role of cholesterol pathway activation in human hepatocellular carcinoma


Finally, we evaluated the mRNA levels and activity of *SREBP2* in a human HCC cohort whose clinicopathological data were available ( $n=65$ ; online supplementary table S3). We found that *SREBP2* mRNA expression did not significantly differ between HCC and corresponding SL (online supplementary figure S26A). In contrast, *SREBP2* transcriptional activity was significantly higher in HCC than in SL (online supplementary figure S26A). Furthermore, *SREBP2* activity was significantly more elevated in HCC samples with poorer prognosis (HCCP) when compared with those with better prognosis (HCCB). When assessing the relationship between *SREBP2* and patients' clinicopathological data, we found that higher activity of the *SREBP2* gene correlates with lower HCC survival rate ( $P < 0.0001$ ; online supplementary figure S26B). This association remained strongly significant after multivariate Cox regression analysis ( $p < 0.0001$ ;

online supplementary table S3), thus implying *SREBP2* activity as an independent prognostic factor for HCC. No relationship between the transcriptional activity of *SREBP2* and other clinicopathological parameters of the patients, including age, gender, aetiology, the presence of cirrhosis, tumour size and tumour grade were detected (online supplementary table S3). A similar correlation with tumour aggressiveness and patients' survival was detected when assessing the levels of *SREBP2* target *HMGCR* in the same sample collection (online supplementary figure S26C). In addition, a significant, positive correlation between the transcription activity of *SREBP2* and the mRNA levels of *HMGCR* was identified ( $p < 0.0001$ ; online supplementary figure S26D). To further validate these results, we analysed the mRNA expression of additional *SREBP2* target genes, including *MVK*, lanosterol synthase (*LSS*), and 24-dehydrocholesterol reductase (*DHCR24*). Noticeably, mRNA expression of these genes correlated with *SREBP2* activity in human HCC samples, but not *SREBP2* mRNA levels (online supplementary figure S27A–C). Importantly, high levels of *MVK*, *LSS* and *DHCR24* were all associated with poor patients' prognosis (online supplementary figure S27D).

Altogether, these data demonstrate that upregulation of *SREBP2* and its transcriptional programme is a molecular feature of aggressive HCC in humans.

### DISCUSSION

A major finding of the present investigation is that loss of *Fasn* only delays tumour initiation, but sgPten/c-Met overexpression could still induce HCC formation in *Fasn* knockout mice. Mechanistically, *Fasn*( $-$ ) HCC showed the feedback activation of *Srebp1/Srebp2*, in accordance with previous studies showing that FAs are key regulators of *Srebp1/Srebp2*.<sup>26</sup> The precise mechanism(s) whereby ablation of *Fasn* increases *Srebp1/Srebp2* activation requires further investigation. Our preliminary observations indicate that the regulation presumably occurs at the protein level, by regulating *Srebp1/Srebp2* nuclear localisation and consequent transcriptional activity. Increased *Srebp1/Srebp2*



**Figure 8** Scheme summarising the compensatory activation of cholesterol biosynthesis following fatty acid synthase (FASN) depletion along hepatocarcinogenesis. In the sgPten/c-Met mouse model, all sgPten/c-Met-injected *Fasn*<sup>fl/fl</sup> mice develop high burden of liver tumours by 8–10 weeks postinjection, with hepatocellular carcinoma (HCC) tissues showing high triglyceride and cholesterol levels. Hepatocarcinogenesis is instead delayed but not abolished by *Fasn* deletion in sgPten/c-Met-injected *Fasn*<sup>LKO</sup> mice. These mice exhibit a high burden of malignant lesions within 14–40 weeks postinjection, with decreased triglyceride levels and increased cholesterol esters. Mechanistically, loss of *Fasn* promotes nuclear localisation and activation of sterol regulatory element binding protein 2 (SREBP2), which upregulates the key enzyme *Hmgcr* of cholesterol biosynthesis, resulting in cholesterol accumulation and, eventually, HCC formation. Noticeably, blocking of cholesterol synthesis via the dominant negative form of SREBP2 (*dnSREBP2*) completely prevents sgPten/c-Met-driven hepatocarcinogenesis in *Fasn* knockout mice. Even when these mice are aged until 50 weeks postinjection, they appear healthy, with no liver tumour nodules visible. Thus, concomitant inhibition of FASN and HMGCR is likely to prevent triglyceride and cholesterol accumulation, leading to strong suppression of hepatocarcinogenesis. Up red arrows and down red arrows indicate upregulation and downregulation, respectively.

activity resulted in the upregulation of genes involved in de novo lipogenesis and cholesterol biosynthesis. However, due to the loss of *Fasn*, de novo lipogenesis rate was clearly repressed, as levels of myristic acid and/or palmitic acid were low in all lipid species, and TAG levels were decreased in *Fasn*(–) HCC tissues. The net outcome of increased SREBP2 activity was the increased expression of genes promoting cholesterologenesis, leading to the enhanced CE levels in *Fasn*(–) HCC. To further substantiate that this phenotype is not limited to sgPten/c-Met HCC model, we investigated the expression of *Hmgcr*, *Mvd* and *Sqle* in *Fasn*(+) and *Fasn*(–) HCCs from PIK3CA/c-Met and PIK3CA/Ras mice. Consistently, elevated expression of these cholesterol biosynthesis genes occurred only in *Fasn*(–) tumour samples (online supplementary figure S28). To the best of our knowledge, this is the first observation of crosstalk between FA synthesis and cholesterol biosynthesis cascades along carcinogenesis. It is worth to note that this biochemical crosstalk is specific for HCC. Indeed, gene expression data from *Fasn*(+) and *Fasn*(–) normal liver tissues did not reveal the upregulation of SREBP1/2 cascade in *Fasn*(–) normal liver (online supplementary figure S3, online supplementary figure S29–S31). Instead, ‘response to stress’, ‘regulation of p38MAPK cascade’ and ‘de novo protein folding’ were among the most significantly upregulated pathways in *Fasn*(–) normal liver (online supplementary figure S31), suggesting that *Fasn* may function to protect normal liver from stress. Clearly, additional studies are required to define the contribution of *Fasn* on normal liver physiology. Furthermore, it remains to be defined how the loss of FASN triggers SREBP1/SREBP2 activity in human and mouse HCC cells. Importantly, in a recent study, it was discovered that SREBP2 is negatively regulated by the p53 tumour suppressor; and suppression of

cholesterogenesis restricted HCC development induced by p53 loss in mice.<sup>27</sup> These data support the major role of cholesterol biosynthesis pathway in hepatocarcinogenesis. Additional studies are needed to delineate the precise mechanism(s), whereby increased SREBP2/HMGCR and the related cholesterol biosynthesis contribute to hepatocarcinogenesis.

The present findings have important clinical implications both in terms of prognosis prediction and innovative therapies. Indeed, our data suggest that SREBP2 activity and cholesterol biosynthesis might be a novel, negative prognostic marker in this tumour type. In terms of therapy perspectives, since the loss of FASN triggers the compensatory upregulation of HMGCR and cholesterol biosynthesis in vitro and in vivo, concomitant inhibition of FASN and HMGCR is likely to prevent this metabolic adaptation, leading to strong decrease of tumour growth in patients with HCC. Our in vivo experiments using dnSREBP2 (figure 5) and in vitro studies using siRNAs against FASN and HMGCR or SREBP2 support this hypothesis (figure 7). Altogether, our data provide important preclinical evidence supporting the testing of co-administration of FASN and HMGCR inhibitors for HCC therapy and prevention.

#### Author affiliations

<sup>1</sup>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China

<sup>2</sup>Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA

<sup>3</sup>School of Pharmaceutical Sciences, Beijing Advanced Innovation Center for Structural Biology, Tsinghua University, Beijing, China

<sup>4</sup>Collaborative Innovation Center for Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China

<sup>5</sup>Department of Oncology, National Center of Gerontology, Beijing Hospital, Beijing, China

<sup>6</sup>School of Pharmacy, Huazhong University of Science and Technology Tongji Medical College, Wuhan, Hubei, China

<sup>7</sup>Department of Oncology and Hematology, The Second Hospital, Jilin University, Changchun, Jilin, China

<sup>8</sup>Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Sardegna, Italy

<sup>9</sup>Beijing University of Chinese Medicine, Beijing, China

<sup>10</sup>Institute of Pathology, University Medicine of Greifswald, Greifswald, Germany

<sup>11</sup>BIOPIIC, Beijing Advanced Innovation Center for Genomics, and School of Life Sciences, Peking University, Beijing, China

<sup>12</sup>Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China

<sup>13</sup>State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology Chinese Academy of Sciences, Beijing, China

<sup>14</sup>Institute of Pathology, University of Regensburg, Regensburg, Germany

<sup>15</sup>Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

**Acknowledgements** The authors would like to thank Dr Clay F Semenkovich (Washington University, St. Louis, Missouri, USA) for providing Fas<sup>fl/fl</sup> mice, Dr Almut Schulze (Comprehensive Cancer Center Mainfranken, Würzburg, Germany) for the dnSrebp2 plasmid, Dr Binbin Liu (Liver Cancer Institute and Zhongshan Hospital of Fudan University, China) for the MHCC97H cell line and Dr Brian Carr (Dokuz Eylul University, Turkey) for the Hep40 cell line.

**Contributors** Study concept and design: LGC, XC, DC; performing the experiments: LC, WC, YQ, JZ, XS, LL, JJ, AC, CC; data analysis: LC, WC, YL, JW, ZM, WK, ZT, ZZ, GS, SR, FD, ME, TO, MP, CC, GP; drafting of the manuscript: LC, WC; revising of the manuscript: LGC, XC, DC; LGC, XC and DC obtained the funding for the study; all authors have access to the study data and have reviewed and approved the final manuscript.

**Funding** This work is supported by National Key R&D Program of China (grant no 2018YFA0506903), National Science Foundation of China (grant no 91857108 and 81470839), National Science and Technology Major Projects for Major New Drugs Innovation and Develop (grant no 2018ZX09711003-004-002), Tsinghua University Initiative Scientific Research Program (grant no 20161080086) to LGC; NIH grants R01CA136606 to XC; P30DK026743 for UCSF Liver Center; Grant from the Italian Association Against Cancer (AIRC; grant no IG 19175) to DC; as well as National Science Foundation of China (grant no 81872253) to LL.

**Competing interests** None declared.

**Patient consent for publication** Obtained.

**Ethics approval** This study was approved by the local ethical committee of the Medical University of Greifswald (approval # BB 67/10).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iD

Xin Chen <http://orcid.org/0000-0002-9588-0164>

## REFERENCES

- Ferlay J, Soerjomataram I, Dikshit R, *et al*. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;136:E359–86.
- Kudo M. Systemic Therapy for Hepatocellular Carcinoma: 2017 Update. *Oncology* 2017;93(Suppl 1):135–46.
- Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. *Cancer Cell* 2012;21:297–308.
- Beloribi-Djefafila S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. *Oncogenesis* 2016;5:e189.
- Röhrlig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. *Nat Rev Cancer* 2016;16:732–49.
- Che L, Pilo MG, Cigliano A, *et al*. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. *Cell Cycle* 2017;16:499–507.
- Calvisi DF, Wang C, Ho C, *et al*. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. *Gastroenterology* 2011;140:1071–83.
- Hu J, Che L, Li L, *et al*. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. *Sci Rep* 2016;6:20484.
- Li L, Pilo GM, Li X, *et al*. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. *J Hepatol* 2016;64:333–41.
- Cao D, Song X, Che L, *et al*. Both de novo synthesized and exogenous fatty acids support the growth of hepatocellular carcinoma cells. *Liver Int* 2017;37:80–9.
- Guri Y, Colombi M, Dazert E, *et al*. mTORC2 Promotes Tumorigenesis via Lipid Synthesis. *Cancer Cell* 2017;32:e12:807–23.
- Kawata S, Takaishi K, Nagase T, *et al*. Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. *Cancer Res* 1990;50:3270–3.
- Singh S, Singh PP, Singh AG, *et al*. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. *Gastroenterology* 2013;144:323–32.
- Zhou YY, Zhu GQ, Wang Y, *et al*. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. *Oncotarget* 2016;7:21753–62.
- Sutter AP, Maaser K, Höpfner M, *et al*. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. *J Hepatol* 2005;43:808–16.
- Cao Z, Fan-Minogue H, Bellovin DI, *et al*. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. *Cancer Res* 2011;71:2286–97.
- Relja B, Meder F, Wilhelm K, *et al*. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. *Int J Mol Med* 2010;26:735–41.
- Xu Z, Hu J, Cao H, *et al*. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway. *Exp Mol Med* 2018;50:e417.
- Chakravarthy MV, Zhu Y, López M, *et al*. Brain fatty acid synthase activates PPARalpha to maintain energy homeostasis. *J Clin Invest* 2007;117:2539–52.
- Postic C, Shiota M, Niswender KD, *et al*. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. *J Biol Chem* 1999;274:305–15.
- Chakravarthy MV, Pan Z, Zhu Y, *et al*. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. *Cell Metab* 2005;1:309–22.
- Chen X, Calvisi DF. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. *Am J Pathol* 2014;184:912–23.
- Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu. Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. *Cell* 2017;169:1327–41. e23.
- Wang C, Che L, Hu J, *et al*. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade. *Liver Int* 2016;36:1176–86.
- Porstmann T, Griffiths B, Chung YL, *et al*. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. *Oncogene* 2005;24:6465–81.
- Jump DB, Tripathy S, Depner CM. Fatty acid-regulated transcription factors in the liver. *Annu Rev Nutr* 2013;33:249–69.
- Moon SH, Huang CH, Houlihan SL, *et al*. p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression. *Cell* 2019;176:564–80.